- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04976062
NIRS-IVUS to Improve Assessment of Coronary Artery Disease Severity in Patients Referred for Transcatheter Aortic Valve Implantation (IMPACTavi)
NIRS-IVUS to Improve Assessment of Coronary Artery Disease Severity in Patients Referred for Transcatheter Aortic Valve Implantation; the IMPACTavi Trial
Study Overview
Status
Conditions
Detailed Description
Concomitant coronary artery disease (CAD) is frequent in patients referred for transcatheter aortic valve replacement (TAVI) and there is evidence for a subsequent prognostic impairment. Percutaneous coronary intervention (PCI) is believed to improve prognosis in selected cases, which is why current guidelines recommend PCI to be considered in case of coronary artery diameter stenosis > 70% in proximal segments. Beyond those cases, selection is hampered by inherent shortcoming of the assessment of CAD severity by angiography alone as well as clinical and complex hemodynamic interactions between both pathologies. In patients with CAD alone, the FDA-cleared near-infrared spectroscopy and intravascular imaging (NIRS-IVUS) dual imaging catheter (Indfraredx, Inc., Bedford, USA) has proven the ability to reliably measure lipid plaque burden as well as to identify patients and plaques at increased risk for future adverse cardiovascular events. NIRS-IVUS imaging offers the unique possibility to improve angiographic CAD severity assessment in patients referred for TAVI, avoiding the influence of hemodynamic interactions and pathophysiological overlap between CAD and severe AS.
The IMPACTavi trial is designed as a prospective, non-randomized cohort study to investigate whether NIRS-IVUS-derived lesion characteristics will allow identification of patients likely to suffer adverse clinical events during clinical follow-up after TAVI. Patients with severe aortic stenosis will be qualified for enrollment if routine coronary angiography during diagnostic workup before TAVI shows evidence of coronary artery disease with at least one native vessel without prior stent implantation and at least one lesion requiring NIRS-IVUS imaging for clinical indications, and if at 30mm of total NIRS-IVUS pullback length in sufficient quality for offline analysis have been obtained. Clinical indication, technique and timing of PCI and TAVI will be at the discretion of the interdisciplinary heart-team. The primary and secondary endpoints will be assessed during clinical follow-up out to 24 months. Findings from NIRS-IVUS imaging will be analyzed on a patient- and lesion-level, in order to evaluate correlations of high- vs. low-risk lesion characteristics to the incidence of patient- and lesion-level MACE.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Bavaria
-
Munich, Bavaria, Germany, 80636
- Recruiting
- Deutsches Herzzentrum München
-
Contact:
- Michael Joner, Prof. Dr. med.
- Phone Number: +49 89 12180
- Email: joner@dhm.mhn.de
-
Contact:
- Tobias Lenz, Dr. med.
- Phone Number: +49 89 12180
- Email: lenzt@dhm.mhn.de
-
Sub-Investigator:
- Tobias Lenz, MD
-
-
-
-
-
Zürich, Switzerland, 8091
- Recruiting
- Universitatsspital Zurich
-
Contact:
- Barbara Stähli, Prof. Dr. med.
- Phone Number: +41 44 255 11 11
- Email: barbara.staehli@usz.ch
-
Contact:
- Rahel Kesterke, Dr. sc. nat.
- Phone Number: +41 43 253 10 37
- Email: rahel.kesterke@usz.ch
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age ≥ 18 years and able to give consent
- Severe aortic stenosis found eligible for transfemoral TAVI by the multi-disciplinary heart team
- Angiographic evidence of coronary artery disease with absence of coronary stents in at least one native coronary artery
- At least 30 mm of total NIRS-IVUS pullback length in sufficient quality for offline analysis of at least one native coronary artery with absence of coronary stents, containing at least one lesion requiring NIRS-IVUS imaging for clinical indications
- Written, informed consent by the patient or her/his legally-authorized representative for participation in the study
- In women with childbearing potential a negative pregnancy test is mandatory
Exclusion Criteria:
- Age < 18years
- Any clinical contraindications to perform NIRS-IVUS
- ST-elevation myocardial infarction or cardiogenic shock within 48h prior to enrollment
- Decompensated aortic valve stenosis requiring emergency TAVI
- History of coronary artery bypass graft (CABG)
- Severe renal failure with estimated glomerular filtration rate <20 ml/min
- Malignancies or other comorbid conditions (resulting in a life expectancy <12 months)
- Inability to fully cooperate with the study protocol
- Known allergy towards P2Y12 receptor antagonists
- Pregnancy
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of major adverse cardiac events as assessed during clinical follow-up and according to current VARC-definitions
Time Frame: 24 months
|
Major adverse cardiac events (MACE) is defined as the composite of all-cause mortality, myocardial infarction, unplanned coronary revascularization and hospital readmission due to acute coronary syndrome
|
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Freedom from NIRS-IVUS-emergent complications as assessed by post-NIRS-IVUS control angiography during initial hospital stay, on average 5 days
Time Frame: initial hospital stay
|
NIRS-IVUS-emergent complications are defined as coronary impairment following performance of NIRS-IVUS imaging
|
initial hospital stay
|
Incidence of acute kidney injury according to RIFLE/AKIN-criteria assessed during initial hospital stay, on average 5 days
Time Frame: initial hospital stay
|
initial hospital stay
|
|
Incidence of major vascular complications according to current VARC-defintions, assessed during initial hospital stay, on average 5 days
Time Frame: initial hospital stay
|
initial hospital stay
|
|
Incidence of major- or life-threatening bleedings according to current VARC-definitions, assessed during initial hospital stay, on average 5 days
Time Frame: initial hospital stay
|
initial hospital stay
|
|
Incidence of any stroke according to current VARC-definitions, assessed during initial hospital stay, on average 5 days
Time Frame: initial hospital stay
|
initial hospital stay
|
|
Incidence of all-cause mortality as assessed during clinical follow-up
Time Frame: 24-months
|
24-months
|
|
Incidence of myocardial infarction as assessed during clinical follow-up according to current VARC-definitions
Time Frame: 24 months
|
24 months
|
|
Incidence of unplanned coronary revascularization as assessed during clinical follow-up
Time Frame: 24 months
|
24 months
|
|
Incidence of hospital readmission as assessed during clinical follow-up
Time Frame: 24 months
|
24 months
|
|
Incidence of any coronary revascularization as assessed during clinical follow-up
Time Frame: 24 months
|
24 months
|
|
Incidence of hospital readmission due to angina pectoris or equivalent as assessed during clinical follow-up
Time Frame: 24 months
|
24 months
|
|
NYHA class as defined by the New York Heart Association Functional Classification assessed at 24-months clinical follow-up
Time Frame: 24 months
|
24 months
|
|
CCS class as defined by the Canadian Cardiovascular Society grading of angina pectoris assessed at 24-months clinical follow-up
Time Frame: 24 months
|
24 months
|
|
Delta left-ventricular ejection fraction at 3- and 12-months follow-up compared to baseline
Time Frame: 24 months
|
24 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael Joner, MD, Deutsches Herzzentrum München
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GE IDE No. T00120
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
San Luigi Gonzaga HospitalRecruitingCoronary Disease | STEMI | Coronary Artery Ectasia | Right Coronary Artery Occlusion | Right Coronary Artery StenosisSpain, Italy
Clinical Trials on Combined near-infrared spectroscopy and intravascular ultrasound imaging (NIRS-IVUS)
-
University Hospital, Motolprofessor Josef Veselka; associate professor Petr Hájek; Martin HorváthCompletedCarotid Atherosclerosis | Restenosis | Carotid Artery Stenting | Near Infrared Spectroscopy | Atherosclerotic PlaqueCzechia
-
InfraredxCompletedMyocardial Infarction | Angina Pectoris | Angina, UnstableUnited States, Canada
-
Erasmus Medical CenterUnknown
-
InfraredxCompletedMyocardial Infarction | Myocardial Ischemia | Coronary Artery Disease | AnginaUnited States
-
Unity Health TorontoUnknownPeripheral Vascular Disease Patient
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSubarachnoid HemorrhageFrance
-
University of CambridgeCambridgeshire and Peterborough NHS Foundation Trust; The Gianna Angelopoulos... and other collaboratorsNot yet recruitingAlzheimer Disease | Mild Cognitive Impairment | Dementia With Lewy Bodies
-
Mount Sinai Hospital, CanadaLondon Health Sciences Centre; Royal Alexandra Hospital; Foothills Medical CentreNot yet recruitingIntraventricular Hemorrhage of Newborn Grade 2 | Intraventricular Hemorrhage of Newborn Grade 3 | Intraventricular Haemorrhage Grade IVCanada
-
Assistance Publique - Hôpitaux de ParisCompletedShock | Cerebral Lesion | Arterial HypotensionFrance
-
Wake Forest University Health SciencesCompleted